Results of a randomised, double-blind, parallel-group study assessing safety and efficacy of 40 mg vs. 20 mg of glatiramer acetate on MRI-measured disease activity in relapsing-remitting multiple sclerosis

被引：0
|
作者：
Rovaris, M.
Cohen, J.
Goodman, A.
Comi, G.
Filippi, M.
机构：
来源：
JOURNAL OF NEUROLOGY | 2006年 / 253卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：144 / 144
页数：1
相关论文
共 50 条
  • [1] Randomised, double-blind, parallel-group, dose-comparison study of glatiramer acetate in relapsing-remitting multiple sclerosis
    Cohen, J.
    Rovaris, M.
    Goodman, A.
    Wynn, D. R.
    Ladkani, D.
    Filippi, M.
    MULTIPLE SCLEROSIS, 2006, 12 : S99 - S100
  • [2] Efficacy and Safety of Fingolimod 0.5 mg and 0.25 mg Versus Glatiramer Acetate 20 mg in Patients with Relapsing-Remitting Multiple Sclerosis - ASSESS Study Group
    Cree, Bruce
    Goldman, Myla
    Corboy, John
    Singer, Barry
    Fox, Edward
    Arnold, Douglas
    Ford, Corey
    Weinstock-Guttman, Bianca
    Bar-Or, Amit
    Mientus, Susanne
    Sienkiewicz, Daniel
    Zhang, Ying
    Karan, Rajesh
    Tenenbaum, Nadia
    NEUROLOGY, 2019, 92 (15)
  • [3] GLANCE: A double-blind, randomised, placebo-controlled, parallel-group safety study of natalizumab (Antegren) in combination with glatiramer acetate (Copaxone) in subjects with relapsing-remitting multiple sclerosis
    Goodman, A
    Bar-Or, A
    Miller, A
    Miller, D
    Panzara, M
    Rossman, H
    Schmierer, K
    Toal, M
    JOURNAL OF NEUROLOGY, 2004, 251 : 176 - 177
  • [4] GLANCE: A double-blind, randomized, placebo-controlled, parallel-group safety study of natalizumab in combination with glatiramer acetate in subjects with relapsing-remitting multiple sclerosis
    Goodman, AD
    Rossman, HS
    Bar-Or, A
    Miller, A
    Miller, D
    Lublin, F
    Khan, O
    Metz, L
    Panzara, M
    Yang, MH
    Toal, M
    Sandrock, A
    NEUROLOGY, 2005, 64 (06) : A277 - A278
  • [5] Statistical comparison of adverse events for glatiramer acetate 20mg vs 40mg for the treatment of relapsing-remitting multiple sclerosis
    Zagmutt, F. J.
    Wu, Y.
    Grinspan, A.
    Kolodny, S.
    Gandhi, S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 599 - 599
  • [6] Results from a phase III, one-year, randomized, double-blind, parallel-group, dose-comparison study with glatiramer acetate in relapsing-remitting multiple sclerosis
    Comi, Giancarlo
    Cohen, Jeffrey A.
    Filippi, Massimo
    MULTIPLE SCLEROSIS, 2008, 14 : S299 - S299
  • [7] The effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a double-blind active extension of the multicentre, randomised, double-blind, parallel-group placebo-controlled study
    Comi, G.
    Abramsky, O.
    Arbizu, T.
    Boiko, A.
    Gold, R.
    Havrdova, E.
    Komoly, S.
    Selmaj, K. W.
    Sharrack, B.
    Filippi, M.
    JOURNAL OF NEUROLOGY, 2008, 255 : 46 - 46
  • [8] A randomised, double-blind, placebo-controlled, parallel study assessing the add-on effect of minocycline in relapsing-remitting multiple sclerosis subjects treated with glatiramer acetate
    Metz, LM
    Li, D
    Myles, ML
    Traboulsee, A
    Duquette, R
    Yong, VW
    MULTIPLE SCLEROSIS, 2005, 11 : S87 - S87
  • [9] Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One) a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study
    Brown, J. William L.
    Cunniffe, Nick G.
    Prados, Ferran
    Kanber, Baris
    Jones, Joanne L.
    Needham, Edward
    Georgieva, Zoya
    Rog, David
    Pearson, Owen R.
    Overell, James
    MacManus, David
    Samson, Rebecca S.
    Stutters, Jonathan
    Ffrench-Constant, Charles
    Wheeler-Kingshott, Claudia A. M. Gandini
    Moran, Carla
    Flynn, Paul D.
    Michell, Andrew W.
    Franklin, Robin J. M.
    Chandran, Siddharthan
    Altmann, Daniel R.
    Chard, Declan T.
    Connick, Peter
    Coles, Alasdair J.
    LANCET NEUROLOGY, 2021, 20 (09): : 709 - 720
  • [10] GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis
    Wolinsky, Jerry S.
    Borresen, T. Erik
    Dietrich, Dennis W.
    Wynn, Daniel
    Sidi, Yulia
    Steinerman, Joshua R.
    Knappertz, Volker
    Kolodny, Scott
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2015, 4 (04) : 370 - 376
12345